• FinUniversity Electronic Library

Login
Search manual

Details

Smith, Robert E.,. Systems thinking in medicine and new drug discovery. Volume one / / by Robert E. Smith. — 1 online resource (xv, 616 pages) : illustrations. — <URL:http://elib.fa.ru/ebsco/1986600.pdf>.

Record create date

12/20/2018

Subject

Drug development.; Pharmaceutical chemistry.; Integrative medicine.; Human biology.; Drug Discovery.; Drug development.; Human biology.; Integrative medicine.; Pharmaceutical chemistry.; MEDICAL / Pharmacology

Collections

EBSCO

Allowed Actions

–

Action 'Read' will be available if you login or access site from another network

Action 'Download' will be available if you login or access site from another network

Group Anonymous
Network Internet
Network User group Action
Finuniversity Local Network All
Read Print Download
Internet Readers
Read Print
Internet Anonymous
  • Contents
  • Preface
  • Chapter One
    • 1.1 Introduction
    • 1.2 Reductionist Thinking and DNA
    • 1.3 Systems Thinking
      • 1.3.1 Definition and the importance of change
      • 1.3.2 Misconceptions that are clarified by systems thinking
      • 1.3.3 Characteristics of systems thinking
      • 1.3.4 The roots of systems thinking
      • 1.3.5 Autopoiesis and Gaia
      • 1.3.6 Systems view of autopoiesis and stem cells
      • 1.3.7 The importance of networks in life
      • 1.3.8 Genetics and systems thinking
      • 1.3.9 Nonlinearity and rhythms in living systems
      • 1.3.10 The –omics, from genomics to personal –omics
      • 1.3.11 A multidimensional, non-linear view of diseases
      • 1.3.12 Drugs that bind to multiple targets
      • 1.3.13 Modularity of biological networks
      • 1.3.14 Going beyond genomics and looking for hidden connections
      • 1.3.15 Tools for understanding metabolism better
      • 1.3.16 Evidence based medicine and the Critical Path Initiative
      • 1.3.17 Cancer Genome Characterization Initiative, CGCI
      • 1.3.18 Systems-based thinking in education, in contrast with reductionist thinking inadvertisements and propaganda
    • 1.4 More systems thinking is needed
    • 1.5 Reductionist thinking is still useful
    • References
  • Chapter Two
    • 2.1 The human ecosystem, holobionts, hologenome and viruses
    • 2.2 The widespread existence of microbes in the human body
    • 2.3 Gut microbiome and the enteric nervous system (ENS
      • 2.3.1 Composition of the gut micr
      • 2.3.2 Interactions and communication between the ENS and the rest of the body
      • 2.3.3 Communication between the gut microbiome, ENS, brain and immune system
      • 2.3.4 The gut microbiota and ENS comprise an entero endocrine organ
    • 2.4 The role of the gut microbiome in preventing diseases
    • 2.5 The role of gut microbiome dysbiosis in causing diseases
      • 2.5.1 The importance of biodiversity
      • 2.5.2 The gut microbiome and inflammation
      • 2.5.3 The benefits of vegan and vegetarian diets
      • 2.5.4 The gut microbiome and cardiovascular diseases
      • 2.5.5 The role of the gut microbiome in stress, anxiety and neurodegenerative diseases
      • 2.5.6 The importance of healthy microbiota in obtaining an effective response to vaccines
      • 2.5.7 The importance of oral health and preventing periodontal disease
    • 2.6 Factors affecting the composition of the microbiome
    • 2.7 Viruses are important, too
    • 2.8 Eukarya in the human microbiome
      • 2.8.1 Introduction to the microbial eukaryotic cells in the human microbiome
      • 2.8.2 Fungi
      • 2.8.3 Protozoa and intestinal worms (helminths)
    • References
  • Chapter Three
    • 3.1 How new drugs are developed
      • 3.1.1 Select a Disease
      • 3.1.2 Select a therapeutic target or phenotype
      • 3.1.3 Find a lead compound
      • 3.1.4 Improve the lead compound
      • 3.1.5 Drug delivery
      • 3.1.6 Manufacturing and cGMP
      • 3.1.7 Clinical trials
      • 3.1.8 Many drugs that were developed and approved had a single therapeutic target
      • 3.1.9 Combinations of drugs are also used and are being developed
      • 3.1.10 Some targets are now known to have formerly unexpected biological roles
      • 3.1.11 Some drugs may be useful in treating other diseases
      • 3.1.12 The Reemergence of Phenotypic Screening
      • 3.1.13 Other new approaches to new drug discovery
    • 3.2 The difference between how prescription drugs, dietary supplements and ‘super-foods’ are developed and used
      • 3.2.1 ‘Superfoods’
      • 3.2.2 Dietary supplements: from amphetamine to fish oil to vitamin D and folic acid
      • 3.2.3 A complex, nonlinear dynamic systems perspective on Ayurveda and Ayurvedic research
      • 3.2.4 Discovery and development of innovative drugs from traditional medicine by integrated chinmedomics strategies in the post-genomic era
      • 3.2.5 A complex systems science perspective for whole systems of complementary and alternative medicine research
      • 3.2.6 A Pilot Feasibility Study of whole-systems Ayurvedic medicine and yoga therapy for weight loss
      • 3.2.7 Prescription drugs and weight loss supplements for weight loss
      • 3.2.8 Prescription drugs: strict protocols and quality management systems, take much longer to reach the market
    • 3.3 Immunotherapy – using one’s own body to cure one’s self
    • 3.4 Synthetic biology and CRISPR technology in new drug development
    • 3.5 Rapid prototyping by 3D printing
      • 3.5.1 Introduction
      • 3.5.2 Biodegradable scaffolds
      • 3.5.3 Other applications of 3D and 4D printing
      • 3.5.4 Other personalized medical devises
    • References
  • Appendix
    • A1.1 Introduction
    • A1.2 Ultraviolet-Visible (UV-Vis) Spectrophotometry and Fluorescence Spectroscopy
    • A1.3 HPLC and UPLC
    • A1.4 Gas Chromatography, GC
    • A1.5 Mass Spectrometry, GC-MS and LC-MS
    • A1.6 Quantitative Analysis
    • A1.7 IR and NMR
    • A1.8 Magnetic Resonance Imaging, MRI
    • References
  • Abbreviations and Acronyms Used
  • Index

Access count: 0 
Last 30 days: 0

Detailed usage statistics